Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

33.43 -0.01 (-0.03%)
Official Closing Price Updated: 7:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate... 
Via Benzinga
Key Dividend Increases From Last Week, Including PepsiCo, Enbridge, GlaxoSmithKline And Cardinal Health
Stocks that raised dividends last week. 
Via Talk Markets
FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children
The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. 
Via The Motley Fool
Calm Markets Day
Despite seriously disappointing April jobless numbers, markets are gaining all the same. 
Via Talk Markets
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move
The closely watched issue of patent rights for COVID-19 vaccines garnered headlines again as the Biden administration came out in favor of a proposal at the World Trade... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Were Hedge Funds Right About Piling Into American Express Company?
Is American Express Company ready to rally soon? The best stock pickers were turning bullish. The number of bullish hedge fund positions rose by 12 in recent months. American Express Company was in 60... 
Via Talk Markets
Novavax Next In List To Start Testing Its COVID-19 Shot In Adolescents
Novavax Inc (NASDAQ: NVAX) has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate. The additional... 
Via Benzinga
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced... 
Via Benzinga
Exposures Product Safety
Pfizer-BioNTech Bullish On COVID-19 Vaccine Trial Results In Infants By September: Reuters
BioNTech SE's (NASDAQ: BNTX) CEO Ugur Sahin says the company, along with its partner Pfizer Inc (NYSE: PFE), could have data from trials testing the... 
Via Benzinga
Exposures COVID-19
2 Undervalued Pharmaceutical Stocks to Buy Now
These two high-dividend stocks might be great additions to your portfolio. 
Via The Motley Fool
GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript
GSK earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
A Heavy News Day And Crypto
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today. 
Via Talk Markets
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its... 
Via Benzinga
Topics Earnings
Exposures Financial
GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 Outlook
GlaxoSmithKline Plc Q1 revenue fell 18% in the first quarter, as the COVID-19 vaccination program delayed sales of its Shingrix shot for shingles. 
Via Talk Markets
Exposures COVID-19
GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 Outlook
GlaxoSmithKline Plc (NYSE: GSK) Q1 revenue fell 18% in the first quarter, as the COVID-19 vaccination program delayed sales of its Shingrix shot for shingles.... 
Via Benzinga
Exposures COVID-19
US To Share Up To 60M AstraZeneca COVID-19 Vaccine Doses
The United States will start to share up to 60 million doses of AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine doses with other countries as they become... 
Via Benzinga
Exposures COVID-19
Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA)... 
Via Benzinga
Exposures COVID-19
Friday Market Report
Schlumberger Ltd of Curação today reported on its Q1 results which were good. 
Via Talk Markets
Oscar Telecast Sells Out Advertising Slots Despite Historically Low Award Show Ratings
ABC has sold out the available advertising slots for Sunday’s Academy Awards telecast, even though ratings on entertainment awards shows have been plummeting and this... 
Via Benzinga
1 Cheap Pharmaceutical Stock to Buy in 2021
GlaxoSmithKline presents a great opportunity for investors this year. 
Via The Motley Fool
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
GlaxoSmithKline's Immunotherapy For Endometrial Cancer Wins FDA Approval
The FDA has granted accelerated approval to GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab) for endometrial cancer. The approval covers... 
Via Benzinga
Exposures Product Safety
Robots
Teva is suffering from fear of the legal risks of its opioid misselling which is overriding good news of its newer drugs. 
Via Talk Markets
Benzinga's Bulls And Bears Of The Week: Alphabet, Coinbase, GE, Quantumscape, Tesla And More
Benzinga has examined the prospects for many investor favorite stocks 
Via Benzinga
Happy News Day
The stock markets are in clover because March retail sales hit 9.8% according to the Department of Commerce. 
Via Talk Markets
Why GlaxoSmithKline Stock Jumped Today
An activist investor is reportedly building a significant position in the drugmaker. 
Via The Motley Fool
BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.